Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Trial Profile

Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2012

At a glance

  • Drugs Boceprevir (Primary) ; Raltegravir
  • Indications Hepatitis C; HIV infections
  • Focus Pharmacokinetics
  • Acronyms OPAL
  • Most Recent Events

    • 12 Sep 2012 Results published in the Clinical Infectious Diseases.
    • 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.
    • 15 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top